Skip to main content
Equibles
NHI logo

NHI · National Health Investors Inc · Metrics

Track NHI — free

Use NHI with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research NHI.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$64.92 -1.43 (-2.16%) At close · Oct 21
S&P 600 member Russell 2000 member Rebalance outlook locked
Going-concern doubt — flagged Aug 10, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Bickford has been a cash basis tenant since 2022 when we received financial information from Bickford raising substantial doubt about its ability to continue as a going concern. As of June 30, 2026, these concerns had not been alleviated.”
View the 10-Q filed Aug 10, 2026
Market Cap
$3.26B
Shares
49.11M
Volume · Oct 21 247.57K Avg daily vol (3M) 353.15K

NHI metrics

87 of 126 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$64.92
Market cap
$3.26B

Price action

20 metrics
Price change (1W)
+1.1%
Price change (30D)
-2.2%
Price change (3M)
-18.2%
Price change (6M)
-20.4%
Price change (YTD)
-13.1%
Price change (1Y)
-12.8%
Trailing year
Price change (5Y)
+15.8%
52-week high
$91.02
52-week low
$63.96
Change from 52-week high
-27.1%
Change from 52-week low
+3.7%
Annualized volatility
23.6%
Annualized volatility (3M)
21.5%
Beta
-0.3
RSI (14D)
47.5
Price vs SMA 50
-3.9%
Price vs SMA 200
-13.6%
Avg volume (3M)
357,647
Relative volume
0.8
Average dollar volume
$25.38M

Company

3 metrics
Sector
Real Estate
Industry
REIT - Healthcare Facilities
Shares outstanding
49.11M

Valuation

14 metrics
P / FFO
13.9×
Company-stated · TTM · reciprocal yield 7.2%
P / AFFO
—
P / E (TTM)
19.2
Trailing earnings · reciprocal yield 5.2%
PEG ratio
0.4
EV / revenue
10.2×
reciprocal yield 9.8%
EV / EBITDA
—
EV / EBIT
—
P / sales
7.4×
reciprocal yield 13.6%
P / book
2.0
reciprocal yield 49.5%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
12.8
reciprocal yield 7.8%
Earnings yield
5.2%

Historical valuation

8 metrics
P / E historical average (3Y)
23.2×
reciprocal yield 4.3%
P / E historical average (5Y)
25.5×
reciprocal yield 3.9%
EV / revenue historical average (3Y)
12.6×
reciprocal yield 7.9%
EV / revenue historical average (5Y)
12.6×
reciprocal yield 8.0%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
5.6%
Trailing 12 months
Payout ratio
105.3%
Shareholder yield
5.5%
Dividend / share (TTM)
$3.70
Dividend growth YoY
+2.2%
Dividend growth streak
1
Last ex-dividend
2026-09-30

Earnings calendar

2 metrics
Next earnings
2026-11-10
Last earnings
2026-08-11

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
38.6%
Gross profit (TTM)
—
Operating profit (TTM)
—
Net income (TTM)
$166.80M
Trailing 12 months
Diluted EPS (TTM)
$3.46
FCF margin
—
Effective tax rate
—

Per share

13 metrics
FFO per diluted share
—
AFFO per diluted share
—
Revenue per diluted share (TTM)
$8.97
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
$3.46
Operating cash flow per diluted share (TTM)
$5.17
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
$0.22
Book value per share
$31.50

Growth

11 metrics
Revenue growth YoY
+33.8%
Year over year
Net income growth YoY
+50.5%
Revenue (TTM)
$432.12M
Trailing 12 months
EPS growth YoY
+45.6%
Shares change YoY
+3.6%
Year over year · more shares
Revenue CAGR (3Y)
+10.5%
Revenue CAGR (5Y)
+2.5%
EPS CAGR (3Y)
+26.8%
EPS CAGR (5Y)
-6.1%
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
10.6%
Return on assets
5.6%
Debt / equity
0.8
Current ratio
—
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
—
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
−$1.24B
Latest balance sheet
Cash & equivalents
$30.39M
Total assets
$2.96B
Total debt
$1.27B

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$248.68M
Capital expenditures (TTM)
$318.29M
R&D (TTM)
—
SG&A (TTM)
—
Stock compensation (TTM)
$10.10M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
306
13F filer change QoQ
-13
Institutional ownership
78.2%
Conviction holders (share of 13F filers)
0.7%
Crowding (high-turnover and private-fund holders)
8.2%
Private-fund adviser ownership
7.9%
Active holders' share change QoQ
-15.3%
Holder tenure
14.0
Price vs estimated holder cost
+9.6%

Ownership (registered funds)

1 metrics
Index-fund ownership
33.1%

Short interest

3 metrics
Short interest
4.9%
Latest settlement · 5.4 days to cover
Days to cover
5.4d
Short-squeeze score
61 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 877860 CUSIP 63633D104 13F (30d) 38 filings 38 filers Visit website Investor relations